406 related articles for article (PubMed ID: 8363363)
1. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.
Frost JJ; Rosier AJ; Reich SG; Smith JS; Ehlers MD; Snyder SH; Ravert HT; Dannals RF
Ann Neurol; 1993 Sep; 34(3):423-31. PubMed ID: 8363363
[TBL] [Abstract][Full Text] [Related]
2. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Sakamoto M
Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
[TBL] [Abstract][Full Text] [Related]
3. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO
Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
[TBL] [Abstract][Full Text] [Related]
4. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
[TBL] [Abstract][Full Text] [Related]
5. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography.
Ouchi Y; Yoshikawa E; Okada H; Futatsubashi M; Sekine Y; Iyo M; Sakamoto M
Ann Neurol; 1999 May; 45(5):601-10. PubMed ID: 10319882
[TBL] [Abstract][Full Text] [Related]
6. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo.
Wong DF; Harris JC; Naidu S; Yokoi F; Marenco S; Dannals RF; Ravert HT; Yaster M; Evans A; Rousset O; Bryan RN; Gjedde A; Kuhar MJ; Breese GR
Proc Natl Acad Sci U S A; 1996 May; 93(11):5539-43. PubMed ID: 8643611
[TBL] [Abstract][Full Text] [Related]
7. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
[TBL] [Abstract][Full Text] [Related]
8. Long-term methamphetamine-induced decreases of [(11)C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey.
Melega WP; Lacan G; Desalles AA; Phelps ME
Synapse; 2000 Mar; 35(4):243-9. PubMed ID: 10657033
[TBL] [Abstract][Full Text] [Related]
9. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism.
Carbon M; Ma Y; Barnes A; Dhawan V; Chaly T; Ghilardi MF; Eidelberg D
Neuroimage; 2004 Apr; 21(4):1497-507. PubMed ID: 15050574
[TBL] [Abstract][Full Text] [Related]
10. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
Lee CS; Samii A; Sossi V; Ruth TJ; Schulzer M; Holden JE; Wudel J; Pal PK; de la Fuente-Fernandez R; Calne DB; Stoessl AJ
Ann Neurol; 2000 Apr; 47(4):493-503. PubMed ID: 10762161
[TBL] [Abstract][Full Text] [Related]
11. [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy.
Berding G; Brücke T; Odin P; Brooks DJ; Kolbe H; Gielow P; Harke H; Knoop BO; Dengler R; Knapp WH
Nuklearmedizin; 2003 Feb; 42(1):31-8. PubMed ID: 12601452
[TBL] [Abstract][Full Text] [Related]
12. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
[TBL] [Abstract][Full Text] [Related]
13. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
14. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428.
Wong DF; Yung B; Dannals RF; Shaya EK; Ravert HT; Chen CA; Chan B; Folio T; Scheffel U; Ricaurte GA
Synapse; 1993 Oct; 15(2):130-42. PubMed ID: 8259524
[TBL] [Abstract][Full Text] [Related]
15. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
[TBL] [Abstract][Full Text] [Related]
16. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.
Fischman AJ; Bonab AA; Babich JW; Palmer EP; Alpert NM; Elmaleh DR; Callahan RJ; Barrow SA; Graham W; Meltzer PC; Hanson RN; Madras BK
Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103
[TBL] [Abstract][Full Text] [Related]
17. PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease.
Ilgin N; Zubieta J; Reich SG; Dannals RF; Ravert HT; Frost JJ
Neurology; 1999 Apr; 52(6):1221-6. PubMed ID: 10214747
[TBL] [Abstract][Full Text] [Related]
18. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
[TBL] [Abstract][Full Text] [Related]
19. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT.
Kim SE; Choi JY; Choe YS; Choi Y; Lee WY
J Nucl Med; 2003 Jun; 44(6):870-6. PubMed ID: 12791812
[TBL] [Abstract][Full Text] [Related]
20. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum.
Kaufman MJ; Madras BK
Synapse; 1991 Sep; 9(1):43-9. PubMed ID: 1796351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
